DOCSLIB.ORG

INTRODUCING-EUROFINS-BEACON-DISCOVERY-The-GPCR-Experts.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

INTRODUCING EUROFINS BEACON DISCOVERY The GPCR Experts Eurofins Discovery welcomes a new company to its organization, Beacon Discovery. Eurofins Beacon Discovery is an industry leader in GPCR drug discovery offering an integrated approach for challenging GPCR targets. The Team has identified in excess of 30 pre-clinical candidates of which more than 20 programs have moved successfully into clinical development. Key to Eurofins Beacon Discovery’s success is the ability to critically evaluate new targets with knowledge acquired from over 20 years of working on this crucial target class. • Industry leading know-how on all aspects of GPCR biology • Complete GPCR drug discovery solution utilizing advanced discovery platforms and technologies • Renowned expertise in prosecuting orphan GPCR targets across therapeutic areas PARTNERING FOR SUCCESS Eurofins Beacon Discovery’s reputation in the field of GPCR discovery is built on the success of its partnerships with biotech and pharma companies worldwide. Beacon scientists take a flexible approach in all of their collaborations with the purpose of designing high quality compounds by employing seasoned medicinal chemistry supported by state-of-the-art computational tools. This chemistry approach combined with a powerful expertise in assay development, mode of action, and biomarker establishment capabilities for over 20 years makes Eurofins Beacon Discovery the partner of choice for your GPCR programs. Join our community of partners who have trusted Eurofins Beacon Discovery to get the biology right in their relentless endeavor to discover and develop life changing drugs. Learn more about GPCR Integrated Drug Discovery and ways to collaborate with Eurofins Beacon Discovery at beacondiscovery.com WORKING WITH EUROFINS BEACON DISCOVERY Support from Concept to Clinic INTEGRATED WORKFLOW DESIGNED WITH YOUR UNIQUE PROGRAM IN MIND Eurofins Beacon Discovery employs an integrated workflow which supports GPCR discovery programs from target validation to providing pre-clinical candidates, with a proven success rate of reaching the clinic. The combination of Eurofins Beacon Discovery’s 600,000 compound screening library and expert biology with proficient medicinal chemistry support is a valid approach to addressing GPCR targets and has been particularly effective for orphan GPCR. Disease Signaling HTS GPR109B GPR109A P2RY11 MRGPRX3 F2RL3 FFAR2 FFAR3 MRGPRX1 FFAR1 F2RL2 MRGPRX4 GPR81 MRGPRX2 OXER1 GPR31 MRGPRD MRGPRG UTR2 MRGPRE Agonist MRGPRF P2RY8 F2R F2RL1 GPR55 GPR18 GPR20 GPR92 GPR35 OXGR1 GPR91 MAS1L P2RY1 TBXA2R P2RY6 P2RY2 PTGER1 P2RY4 MAS1 GPR132 GPR65 PTGER3PTGFR GPR4 GPR68 PTGER2 PTAFR GPR34 600 K PTGDR GPR171 GPR87 PTGER4PTGIR P2RY14 P2RY12 P2RY13 EBI2 LGR6 CYSLTR1 LGR5 CYSLTR2 LGR4 GPR17 LHCGRTSHR GPR174 P2RY10 FSHR GPR23 RXFP2 LPAR6 4R RXFP1 GPR152 LTB OP Antagonist LTB4R2 GPR85OPN3N5 C5AR1 GPR173 C5L2 GPR1 GPBAR1GPR27 C3AR1 CMKLR1 GPR88 Compounds GPR135 GPR33 CRTH2 GPR62 GPR32R1 GPR61 FP G FPR2 PR78 GPR26 FPR3 GPR75 KISS1R GPR150 GALR1 GALR2 ADR GALR3 ADRA2AA MCHR1 PAN/NAM 2 ADRA2 C MCHR2 OPRL1K1 Lead ADRA1BB ADRA1A OPR ADRA1D OPRD1 OPRM1 HTR4 NPBWR1 Expansion HRH2 NPBWR2 HITS DRD3 SSTR1 SSTR4 β DRD2 -Arrestin DRD4 SSTR2 ADRB2 SSTR3 ADRB1 SSTR5 GPCR ADRB3 GPER RXFP3 HTR6 RXFP4 HTR1F Series AGTRL1 HTR1E GPR25 HTR1D GPR15 HTR1B AGTR1 HTR1A Class A AGTR2 DRD5 BDKRB1 DRD1 BDKRB2 HTR7 CXCR7 HTR5A GPR182 TAAR8 CCBP2 TAAR6 XCR1 TAAR9 CCRL2 CX3CR1 Virtual Screening TAAR5 TAAR3 CCR8 TAAR2 CCR4 CCR1 TAAR1 CCR3 HRH1 CCR2 HTR2C CCR5 HTR2A CXCR1 α HTR2B CXCR2 CHRM5 CXCR5 CHRM1 CCR10 CHRM3 CXCR3 β CHRM4 CXCR4 CHRM2 CXCR6 (Billions of Compounds) HRH4 CCRL1 γ HRH3 CCR9 EDG3 CCR6 EDG1 CCR7 EDG5 GPR161 EDG8 GPR101 EDG6 GPR84 Class B Class C GPR50 EDG4 MTNR1A EDG2 MTNR1B EDG7 GPR151 MC5R GPR82 MC4R GPR141 MC3R GPR160 MC2R GPR148 MC1R GPR149 GPR6 GPR153 GPR3 GPR162 GABBR2 GPR12 CNR2 CASR GPRC6A CNR1 GRM1 GRM5 GPR119 GRM2 GRM3 Functional & Binding ADORA2B GRM6 GPCR Assays Available ADORA2A GRM7 ADORA3 GRM4 ADORA1GPR52 GRM8 GPR21 GABBR1 Binding NTSR2 CALCR β-Arrestin NTSR1 CALCRL MLNR CRHR1 GHSR CRHR2 Calcium GLP2R GLP1R NMU2R GCGR cAMP NMU1R GIPR GPR39TRHR PTHR1 PTHR2 Internalization GHRHR ADCYAP1R1 γ GPR142 VIPR2 GTP S SCTR GPR139PPYR1 VIPR1 GPR146 NPY1R DARC NPY5R GPR176 GPR22 GPR37 PRLHR GPR37L1 GPR83 EDNRA EDNRB BRS3 NPY2R GRPR NMBR GPR103 GPR19 GPR45 GPR120 G-Proteins NPFFR2 NPFFR1 HCRTR2 TACR3 TACR1 HCRTR1 TACR2 OXTR CCKBR CCKAR AVPR2 NPSR1 GPR63 AVPR1B GNRHR AVPR1A PROKR2 PROKR1 Mechanistic Studies & β-Arrestin Literature Vetting GPCR Targets Alternatives Lead Clinical Optimization Candidate Tool Compounds HO Synthesis & Testing N Profile Optimization Expression In vitro Pharmacology Medicinal Chemistry Primary Cell Biology Computational Approaches In vivo Model Development ADME/PK TOX/Safety Figure 1. Take advantage of Eurofins Beacon Discovery’s sophisticated and integrated workflow to fast-track your GPCR drug discovery programs. For more information on Eurofins Beacon Discovery and how we can support your GPCR discovery programs, please visit beacondiscovery.com © 2021 Eurofins Discovery. All Rights Reserved. 21243 061521.
Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion

    Strategies to Increase ß-Cell Mass Expansion

    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
  • Single-Cell Rnaseq Reveals Seven Classes of Colonic Sensory Neuron

    Single-Cell Rnaseq Reveals Seven Classes of Colonic Sensory Neuron

    Gut Online First, published on February 26, 2018 as 10.1136/gutjnl-2017-315631 Neurogastroenterology ORIGINAL ARTICLE Gut: first published as 10.1136/gutjnl-2017-315631 on 26 February 2018. Downloaded from Single-cell RNAseq reveals seven classes of colonic sensory neuron James R F Hockley,1,2 Toni S Taylor,1 Gerard Callejo,1 Anna L Wilbrey,2 Alex Gutteridge,2 Karsten Bach,1 Wendy J Winchester,2 David C Bulmer,1 Gordon McMurray,2 Ewan St John Smith1 ► Additional material is ABSTRact pathways to the central nervous system (CNS).1 In published online only. To view Objective Integration of nutritional, microbial and the colorectum, sensory innervation is organised please visit the journal online (http:// dx. doi. org/ 10. 1136/ inflammatory events along the gut-brain axis can alter into two main pathways: thoracolumbar (TL) spinal gutjnl- 2017- 315631). bowel physiology and organism behaviour. Colonic afferents projecting via the lumbar splanchnic sensory neurons activate reflex pathways and give nerve (LSN) and lumbosacral (LS) spinal afferents 1Department of Pharmacology, University of Cambridge, rise to conscious sensation, but the diversity and projecting via the pelvic nerve (PN) that are respon- Cambridge, UK division of function within these neurons is poorly sible for transducing conscious sensations of full- 2Neuroscience and Pain understood. The identification of signalling pathways ness, discomfort, urgency and pain, in addition to Research Unit, Pfizer, contributing to visceral sensation is constrained by a reflex actions.2 Cambridge, UK paucity of molecular markers. Here we address this by Visceral sensory afferents act to maintain many comprehensive transcriptomic profiling and unsupervised aspects of GI physiology, such as continence and Correspondence to James R F Hockley, Department clustering of individual mouse colonic sensory neurons.
  • F2RL2 Antibody Cat

    F2RL2 Antibody Cat

    F2RL2 Antibody Cat. No.: 56-323 F2RL2 Antibody F2RL2 Antibody immunohistochemistry analysis in formalin fixed and paraffin embedded human heart tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human This F2RL2 antibody is generated from rabbits immunized with a KLH conjugated IMMUNOGEN: synthetic peptide between 21-50 amino acids from the N-terminal region of human F2RL2. TESTED APPLICATIONS: IHC-P, WB For WB starting dilution is: 1:1000 APPLICATIONS: For IHC-P starting dilution is: 1:10~50 PREDICTED MOLECULAR 43 kDa WEIGHT: September 25, 2021 1 https://www.prosci-inc.com/f2rl2-antibody-56-323.html Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: F2RL2 Proteinase-activated receptor 3, PAR-3, Coagulation factor II receptor-like 2, Thrombin ALTERNATE NAMES: receptor-like 2, F2RL2, PAR3 ACCESSION NO.: O00254 GENE ID: 2151 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References Coagulation factor II (thrombin) receptor-like 2 (F2RL2) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins.
  • The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes S

    The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes S

    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/02/mol.116.107904.DC1 1521-0111/91/5/518–532$25.00 https://doi.org/10.1124/mol.116.107904 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:518–532, May 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes s Katharina Simon, Nicole Merten, Ralf Schröder, Stephanie Hennen, Philip Preis, Nina-Katharina Schmitt, Lucas Peters, Ramona Schrage,1 Celine Vermeiren, Michel Gillard, Klaus Mohr, Jesus Gomeza, and Evi Kostenis Molecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology (K.S., N.M., Ral.S., S.H., P.P., N.-K.S, L.P., J.G., E.K.), Research Training Group 1873 (K.S., E.K.), Pharmacology and Toxicology Section, Institute of Pharmacy (Ram.S., K.M.), University of Bonn, Bonn, Germany; UCB Pharma, CNS Research, Braine l’Alleud, Belgium (C.V., M.G.). Downloaded from Received December 16, 2016; accepted March 1, 2017 ABSTRACT Pairing orphan G protein–coupled receptors (GPCRs) with their using eight distinct functional assay platforms based on label- cognate endogenous ligands is expected to have a major im- free pathway-unbiased biosensor technologies, as well as molpharm.aspetjournals.org pact on our understanding of GPCR biology. It follows that the canonical second-messenger or biochemical assays. Appraisal reproducibility of orphan receptor ligand pairs should be of of GPR17 activity can be accomplished with neither the coapplica- fundamental importance to guide meaningful investigations into tion of both ligand classes nor the exogenous transfection of partner the pharmacology and function of individual receptors.
  • Genome-Wide Prediction of Small Molecule Binding to Remote

    Genome-Wide Prediction of Small Molecule Binding to Remote

    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.04.236729; this version posted August 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Genome-wide Prediction of Small Molecule Binding 2 to Remote Orphan Proteins Using Distilled Sequence 3 Alignment Embedding 1 2 3 4 4 Tian Cai , Hansaim Lim , Kyra Alyssa Abbu , Yue Qiu , 5,6 1,2,3,4,7,* 5 Ruth Nussinov , and Lei Xie 1 6 Ph.D. Program in Computer Science, The Graduate Center, The City University of New York, New York, 10016, USA 2 7 Ph.D. Program in Biochemistry, The Graduate Center, The City University of New York, New York, 10016, USA 3 8 Department of Computer Science, Hunter College, The City University of New York, New York, 10065, USA 4 9 Ph.D. Program in Biology, The Graduate Center, The City University of New York, New York, 10016, USA 5 10 Computational Structural Biology Section, Basic Science Program, Frederick National Laboratory for Cancer Research, 11 Frederick, MD 21702, USA 6 12 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel 13 Aviv, Israel 7 14 Helen and Robert Appel Alzheimer’s Disease Research Institute, Feil Family Brain & Mind Research Institute, Weill 15 Cornell Medicine, Cornell University, New York, 10021, USA * 16 [email protected] 17 July 27, 2020 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.04.236729; this version posted August 5, 2020.
  • Edinburgh Research Explorer

    Edinburgh Research Explorer

    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Monitoring Nociception by Analyzing Gene Expression Changes in the Central Nervous System of Mice

    Monitoring Nociception by Analyzing Gene Expression Changes in the Central Nervous System of Mice

    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2010 Monitoring nociception by analyzing gene expression changes in the central nervous system of mice Asner, I N Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-46678 Dissertation Originally published at: Asner, I N. Monitoring nociception by analyzing gene expression changes in the central nervous system of mice. 2010, University of Zurich, Vetsuisse Faculty. Monitoring Nociception by Analyzing Gene Expression Changes in the Central Nervous System of Mice Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich von Igor Asner von St. Cergue VD Promotionskomitee Prof. Dr. Peter Sonderegger Prof. Dr. Kurt Bürki Prof. Dr. Hanns Ulrich Zeilhofer Dr. Paolo Cinelli (Leitung der Dissertation) Zürich, 2010 Table of contents Table of content Curriculum vitae 6 Publications 9 Summary 11 Zusammenfassung 14 1. Introduction 17 1.1. Pain and nociception 17 1.1.1 Nociceptive neurons and Mechanoceptors 18 1.1.2 Activation of the nociceptive neurons at the periphery 21 1.1.2.1 Response to noxious heat 22 1.1.2.2 Response to noxious cold 23 1.1.2.3 Response to mechanical stress 24 1.1.3 Nociceptive message processing in the Spinal Cord 25 1.1.3.1 The lamina I and the ascending pathways 25 1.1.3.2 The lamina II and the descending pathways 26 1.1.4 Pain processing and integration in the brain 27 1.1.4.1 The Pain Matrix 27 1.1.4.2 Activation of the descending pathways 29 1.1.5 Inflammatory Pain 31 1.2.
  • Background the Hypothetical GPRC6A Sensing Pathway

    Background the Hypothetical GPRC6A Sensing Pathway

    Modulation of GPRC6A Signaling to Mitigate Tauopathies Chao Ma1,2, Jerry Hunt1,3, Leslie Sandusky PhD1,3, William Fraser1,3, Ronald Alvarez1,3, Dali Zheng PhD1,4, Siddharth Kamath PhD1,2, Chad Dickey PhD1,4, Hans Bräuner-Osborne PhD5, Daniel Sejer Pedersen PhD5, Kevin Nash PhD1,2, Dave Morgan PhD1,2, Daniel Lee PhD1,3 1:Byrd Alzheimer‘s Institute, University of South Florida, Tampa, FL 33613, USA. 2:Morsani College of Medicine, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL 33612, USA. 3:College of Pharmacy, Department of Pharmaceutical Sciences, University of South Florida, Tampa, FL 33612, USA. 4:Morsani College of Medicine, Department of Molecular Medicine, University of South Florida, Tampa, FL 33612, USA. 5:Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 162, 2100 Copenhagen, Denmark Background GPRC6A Allosteric Antagonists Decreased Tau Expression Microtubule associated protein named tau, often becomes hyperphosphorylated and aggregates to form pathological neurofibrillary tangles in several age-associated neurodegenerative diseases known as tauopathies. Clinical phenotypes of tauopathies manifest as cognitive impairment, behavior disturbances and motor impairment. The aggregation of tau remains a central target for drug discovery, but currently no disease-modifying treatments exist. Our group has recently uncovered a unique interaction between L-arginine metabolism and tauopathies. We found that the depletion of L-arginine by overexpressing the metabolizing enzyme arginase 1 and arginine deiminase significantly reduced tau pathology in transgenic mouse models. We speculate that these effects associate with increased autophagy through amino acid sensing. G protein-coupled receptor (GPCR), family C, group 6, member A (GPRC6A) was deorphanized by binding to basic L-α amino acids, like L- arginine.
  • G Protein-Coupled Receptors in Stem Cell Maintenance and Somatic Reprogramming to Pluripotent Or Cancer Stem Cells

    G Protein-Coupled Receptors in Stem Cell Maintenance and Somatic Reprogramming to Pluripotent Or Cancer Stem Cells

    BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-14-250 Title: G protein-coupled receptors in stem cell maintenance and somatic reprogramming to pluripotent or cancer stem cells Article Type: Mini Review Keywords: G protein-coupled receptors; stem cell maintenance; somatic reprogramming; cancer stem cells; pluripotent stem cell Corresponding Author: Ssang-Goo Cho Authors: Ssang-Goo Cho1,*, Hye Yeon Choi1, Subbroto Kumar Saha1, Kyeongseok Kim1, Sangsu Kim1, Gwang-Mo Yang1, BongWoo Kim1, Jin-hoi Kim1 Institution: 1Department of Animal Biotechnology, Animal Resources Research Center, and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, Republic of Korea, UNCORRECTED PROOF 1 G protein-coupled receptors in stem cell maintenance and somatic reprogramming to 2 pluripotent or cancer stem cells 3 4 Hye Yeon Choi, Subbroto Kumar Saha, Kyeongseok Kim, Sangsu Kim, Gwang-Mo 5 Yang, BongWoo Kim, Jin-hoi Kim, and Ssang-Goo Cho 6 7 Department of Animal Biotechnology, Animal Resources Research Center, and 8 Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 9 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, Republic of Korea 10 * 11 Address correspondence to Ssang-Goo Cho, Department of Animal Biotechnology and 12 Animal Resources Research Center. Konkuk University, 120 Neungdong-ro, Gwangjin- 13 gu, Seoul 143-701, Republic of Korea. Tel: 82-2-450-4207, Fax: 82-2-450-1044, E-mail: 14 [email protected] 15 16 17 18 19 1 UNCORRECTED PROOF 20 Abstract 21 The G protein-coupled receptors (GPCRs) compose the third largest gene family in the 22 human genome, representing more than 800 distinct genes and 3–5% of the human genome.
  • A Comprehensive Network and Pathway Analysis of Human Deafness Genes

    A Comprehensive Network and Pathway Analysis of Human Deafness Genes

    Otology & Neurotology 34:961Y970 Ó 2013, Otology & Neurotology, Inc. A Comprehensive Network and Pathway Analysis of Human Deafness Genes *Georgios A. Stamatiou and †Konstantina M. Stankovic *Department of Otolaryngology, Hippokration General Hospital, University of Athens, Athens, Greece; and ÞDepartment of Otology and Laryngology, Harvard Medical School and Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A. Objective: To perform comprehensive network and pathway factor beta1 (TGFB1) for Group 1, MAPK3/MAPK1 MAP kinase analyses of the genes known to cause genetic hearing loss. (ERK 1/2) and the G protein coupled receptors (GPCR) for Study Design: In silico analysis of deafness genes using inge- Group 2, and TGFB1 and hepatocyte nuclear factor 4 alpha (HNF4A) nuity pathway analysis (IPA). for Group 3. The nodal molecules included not only those known Methods: Genes relevant for hearing and deafness were iden- to be associated with deafness (GPCR), or with predisposition to tified through PubMed literature searches and the Hereditary otosclerosis (TGFB1), but also novel genes that have not been Hearing Loss Homepage. The genes were assembled into 3 groups: described in the cochlea (HNF4A) and signaling kinases (ERK 1/2). 63 genes that cause nonsyndromic deafness, 107 genes that cause Conclusion: A number of molecules that are likely to be key nonsyndromic or syndromic sensorineural deafness, and 112 genes mediators of genetic hearing loss were identified through three associated with otic capsule development and malformations. Each different network and pathway analyses. The molecules included group of genes was analyzed using IPA to discover the most new candidate genes for deafness.
  • An Overview on G Protein-Coupled Receptor-Induced Signal Transduction in Acute Myeloid Leukemia

    An Overview on G Protein-Coupled Receptor-Induced Signal Transduction in Acute Myeloid Leukemia

    An overview on G protein-coupled receptor-induced signal transduction in Acute Myeloid Leukemia 1* 1,3 4,5,6 2* Frode Selheim , Elise Aasebø , Catalina Ribas and Anna M. Aragay 1The Proteomics Unit at the University of Bergen, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5020 Bergen, Norway; 3 Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021 Bergen, Norway; [email protected]. 2Departamento de Biologia Celular. Instituto de Biología Molecular de Barcelona (IBMB-CSIC), Spanish National Research Council (CSIC), Baldiri i Reixac, 15, 08028 Barcelona, Spain; [email protected]. 4Departamento de Biología Molecular and Centro de Biología Molecular “Severo Ochoa” (UAM-CSIC), 28049 Madrid, Spain; 5Instituto de Investigación Sanitaria La Princesa, 28006 Madrid, Spain; 6CIBER de Enfermedades Cardiovasculares, ISCIII (CIBERCV), 28029 Madrid, Spain, [email protected] * Corresponding authors: Frode Selheim Adr: Jonas Lies vei 91, 5020 Bergen, Norway Email: [email protected], Tel:+4755586091 Anna M. Aragay Adr: Baldiri i Reixac, 15, 08028 Barcelona. Spain. E-mail: [email protected]; Tel.: +934098671 1 Abstract Background: Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by uncontrolled proliferation of precursor myeloid-lineage cells in the bone marrow. AML is also characterized with patients with poor long-term survival outcomes due to relapse. Many efforts have been made to understand the biological heterogeneity of AML and the challenges to develop new therapies are therefore enormous. G protein-coupled receptors (GPCRs) are a large attractive drug targeted family of transmembrane proteins, and aberrant GPCR expression and GPCR-mediated signaling have been implicated in leukemogenesis of AML.